Document Detail


Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
MedLine Citation:
PMID:  22111941     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Kinase inhibitors have been hailed as a breakthrough in the treatment of cancer. Extensive research is now being devoted to the development of kinase inhibitors as a treatment for many nonmalignant diseases. However, the use of kinase inhibitors in both malignant and nonmalignant diseases is also associated with side effects and the development of resistance. It may be worthwhile to explore whether cell-specific delivery of kinase inhibitors improves therapeutic efficacy and reduces side effects.
AREAS COVERED: This review aims to provide an overview of the preclinical studies performed to examine the specific targeting of kinase inhibitors in vitro and in vivo. It gives an introduction to kinase signaling pathways induced during disease, along with the possible problems associated with their inhibition. It also discusses the studies on specific delivery and shows that altering the specificity of kinase inhibitors by targeting methods improves their effectivity and safety.
EXPERT OPINION: Compared with the delivery of cytotoxic compounds, the specific delivery of kinase inhibitors has not yet been studied extensively. The studies discussed in this review provide an insight into methods used to target kinase inhibitors to different organs. The targeting of different kinase inhibitors has improved their therapeutic possibilities, but many questions still remain to be studied.
Authors:
Marike Marjolijn van Beuge; Klaas Poelstra; Jai Prakash
Publication Detail:
Type:  Journal Article; Review     Date:  2011-11-23
Journal Detail:
Title:  Expert opinion on drug delivery     Volume:  9     ISSN:  1744-7593     ISO Abbreviation:  Expert Opin Drug Deliv     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-22     Completed Date:  2012-05-29     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228421     Medline TA:  Expert Opin Drug Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  59-70     Citation Subset:  IM    
Affiliation:
University of Groningen, University Centre for Pharmacy, Department of Pharmacokinetics, Toxicology & Targeting, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands. m.m.van.beuge@rug.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiovascular Diseases / drug therapy*,  enzymology
Drug Delivery Systems / methods*
Drug Resistance
Humans
Kidney Diseases / drug therapy*,  enzymology
Liver Cirrhosis / drug therapy*,  enzymology
Neoplasms / drug therapy*,  enzymology
Protein Kinase Inhibitors / administration & dosage*,  adverse effects,  therapeutic use
Protein Kinases / chemistry,  metabolism
Chemical
Reg. No./Substance:
0/Protein Kinase Inhibitors; EC 2.7.-/Protein Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-...
Next Document:  The long-term outcome of patients with polycystic liver disease treated with lanreotide.